Acta Scientific Microbiology (ISSN: 2581-3226)

Short Communication Volume 4 Issue 11

COVID-19 Vaccination in Pregnant Women

Attapon Cheepsattayakorn1,3*, Ruangrong Cheepsattayakorn2 and Porntep Siriwanarangsun3

110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
3Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: September 04, 2021; Published: October 20, 2021


A recent study in the USA of a total of 35,691 pregnant participants 16 to 54 years of age from December 14, 2020, to February 28, 2021 [1] was conducted by using data from the v-safe pregnancy registry [2], “v-safe after vaccination health checker” surveillance system [3], and the Vaccine Adverse Event Reporting System (VAERS, a national spontaneous-reporting (passive-surveillance) system established in 1990 and administered by the US CDC and the US FDA) [4], the three US vaccine safety monitoring systems for characterization the initial safety of mRNA COVID-19 vaccines in pregnant participants [1]. Of 3,958 mRNA-vaccine (Pfizer/BioNTech vaccine, Moderna vaccine)-received-pregnant participants registered in the v-safe pregnancy registry, 115 (13.9%) of 827 completed pregnant participants had a pregnant loss and 712 (86.1%) had a live birth (mostly among third-trimester-COVID-19-vaccinated pregnant participants) [1]. Preterm birth (9.4%) and small-size-gestational age (3.2%) were the adverse neonatal outcomes [1]. The study revealed no neonatal death [1].



  1. Shimabukuro TT., et al. “Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons”. The New England Journal of Medicine 24 (2021): 2273-2282.
  2. United States Centers for Disease Control and Prevention. V-safe pregnancy surveillance (amendment) (2021).
  3. United States Centers for Disease Control and Prevention. V-safe active surveillance for COVID-19 vaccine safety (2021).
  4. Shimabukuro TT., et al. “Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)”. Vaccine 33 (2015): 4398-4405.
  5. Dugas C and Slane VH. “Miscarriage”. In: StatPearls. Treasure Island, FL: StatPearls Publishing (2021).
  6. Gynecologists’ Committee on Practice Bulletins-Gynecology. “ACOG practice bulletin no. 200: early pregnancy loss”. Obstetrics and Gynecology5 (2018): e197-e207.
  7. Practice Committee of the American Society for Reproductive Medicine. “Evaluation and treatment of recurrent pregnancy loss: a committee opinion”. Fertility and Sterility 98 (2012): 1103-1111.
  8. Hoyert DL and Gregory ECW. “Cause-of-death data from the fetal death file, 2015-2017”. National Vital Statistics Reports4 (2020): 1-20.
  9. MacDorman MF and Gregory ECW. “Fetal and perinatal mortality: United States, 2013”. National Vital Statistics Reports 8 (2015): 1-24.
  10. Panagiotakopoulos L., et al. “Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink”. Obstetrics and Gynecology 136 (2020): 1086-1094.
  11. Ferré C., et al. “Effects of maternal age and age-specific preterm birth rates-United States, 2007 and 2014”. Morbidity and Mortality Weekly Report 65 (2016): 1181-1184.
  12. United States Centers for Disease Control and Prevention. Percentage of births born preterm by state (2021).
  13. Boghossian NS., et al. “Morbidity and mortality in small for gestational age infants at 22 to 29 weeks’ gestation”. Pediatrics 2 (2018): e20172533.
  14. Francis A., et al. “Customized vs INTERGROWTH-21st standards for the assessment of birthweight and stillbirth risk at term”. American Journal of Obstetrics and Gynecology 218 (2018): S692-S699.
  15. “Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005”. Morbidity and Mortality Weekly Report 57 (2008): 1-5.
  16. United States Centers for Disease Control and Prevention. Infant mortality rates by state (2021).
  17. Moro PL., et al. “Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System”. American Journal of Obstetrics and Gynecology5 (2011): 473 e1-473.e9.
  18. Rottenstreich A., et al. “Efficient maternofetal transplacental transfer of anti-SARS_CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination”. (2021).
  19. Gray KJ., et al. “COVID-19 vaccine response in pregnant and lactating women: a cohort study”. American Journal of Obstetrics and Gynecology (2021).
  20. Paul G and Chad R. “Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination-a case report”. BMC Pediatrics 21 (2021): 138.
  21. Gill L and Jones CW. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in neonatal cord blood after vaccination in pregnancy”. Obstetrics and Gynecology5 (2021): 894-896.
  22. United States Centers for Disease Control and Prevention. “COVID-19 vaccines while pregnant or breastfeeding” (2021).
  23. Goodman T. “Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women”. AFRO Webinar (2021).


Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Vaccination in Pregnant Women”. Acta Scientific Microbiology 4.11 (2021): 46-48.


Acceptance rate33%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US